Sign In
Buy GRCL
$10.25
+0 (+0%)
At Close: May 20, 2024
Gracell Biotechnologies to Report Second Quarter 2023 Financials on Monday, August 14, 2023
04:02pm, Monday, 31'st Jul 2023
SAN DIEGO and SUZHOU, China and SHANGHAI, China, July 31, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedica
Gracell Biotechnologies (GRCL) Surges 62% in a Week: Here's Why
12:58pm, Wednesday, 14'th Jun 2023
Shares of Gracell (GRCL) increase after it reported positive data from two clinical studies, which evaluated its experimental CAR T cell therapy drug in patients with B-cell non-hodgkin's lymphoma and
Why Shares of Gracell Biotechnologies Jumped Tuesday
03:29pm, Tuesday, 13'th Jun 2023
Two analysts upgraded their ratings for Gracell Biotechnologies' stock. Over the weekend, Gracell announced positive follow-up trial data regarding its lead therapy.
First disclosure of data from Phase 1 study of the donor-derived allogeneic CAR-T GC007g shows 100% overall response rate (ORR) and a favorable safety profile for treatment of relapsed/refractory B-ce
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
04:19pm, Wednesday, 10'th May 2023
SAN DIEGO and SUZHOU, China and SHANGHAI, China, May 10, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicat
Gracell Biotechnologies to Report First Quarter 2023 Financials on Monday, May 15, 2023
04:00pm, Tuesday, 02'nd May 2023
SAN DIEGO and SUZHOU, China and SHANGHAI, China, May 02, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicat
Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F at 2023 ASCO Annual Meeting
10:15am, Wednesday, 26'th Apr 2023
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China , April 26, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical co
Orbimed Advisors Now Owns 11.2% of Gracell Biotechnologies
10:33pm, Monday, 03'rd Apr 2023
Fintel reports that Orbimed Advisors has filed a 13D form with the SEC disclosing ownership of 7.58MM shares of Gracell Biotechnologies Inc.
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
04:10pm, Wednesday, 22'nd Mar 2023
SAN DIEGO and SUZHOU, China and SHANGHAI, China, March 22, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical
Gracell Biotechnologies Inc. (GRCL) Q4 2022 Earnings Call Transcript
12:03pm, Monday, 13'th Mar 2023
Gracell Biotechnologies Inc. (NASDAQ:GRCL ) Q4 2022 Earnings Conference Call March 13, 2023 8:00 AM ET Company Participants Kevin Yili Xie - Chief Financial Officer William Wei Cao - Founder, Chairman
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
08:46am, Tuesday, 14'th Feb 2023
SAN DIEGO, Calif., and SUZHOU, China and SHANGHAI, China, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage bioph
Penny Stocks To Buy: 4 To Watch With Big News In February
09:31am, Friday, 03'rd Feb 2023
Penny stocks with news to watch this week. The post Penny Stocks To Buy: 4 To Watch With Big News In February appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
7 Cheap But Risky Biotech Stocks
01:58pm, Wednesday, 18'th Jan 2023
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.
Gracell Biotechnologies Inc. (GRCL) Q3 2022 Results - Earnings Call Transcript
12:28pm, Monday, 14'th Nov 2022
Gracell Biotechnologies Inc. (NASDAQ:GRCL ) Q3 2022 Results Earnings Conference Call November 14, 2022 8:00 AM ET Company Participants Kevin Yili Xie - Chief Financial Officer William Wei Cao - Founde
BCMA/CD19 dual-targeting FasTCAR-T GC012F demonstrated 100% ORR and 100% MRD negativity in the 13 patients treated SAN DIEGO, Calif., SUZHOU and SHANGHAI, China , Nov. 3, 2022 /PRNewswire/ -- Gracell
